Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Erlotinib monotherapy for advanced non-small-cell lung cancer at a medical center in northern taiwan

  • In: Hospital Pharmacy Posters
  • At: Lisbon (Portugal) (2010)
  • Type: Poster
  • Poster code: HPS-P-114
  • By: CHEN, Ying-Ying (Cathy General Hospital, Taipei, China Taiwan)
  • Co-author(s): Kao, Chi-Lan (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
    Huang, Wan-Tsui (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
    Lin, Hsi-Yen (Department of Pharmacy, Cathay General Hospital, TAIPEI, China Taiwan)
  • Abstract:

    INTRODUTION: Erlotinib is one of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) that are the standard therapies in advanced non-small-cell lung cancer (NSCLC) and is tolerable for some patients unfit for chemotherapy. AIMS: To evaluate the efficacy and tolerability of erlotinib monotherapy. METHODS: From March

    ..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses